Table 1.
Current 14-3-3 PPI modulators.
| Compound | Targeted PPI | Relevant disease | Reference |
|---|---|---|---|
| PPI inhibitors | |||
| BV01, BV101 | 14-3-3σ/c-abl | CML | [83] |
| BV02 | 14-3-3σ/c-abl | CML | [81] |
| BV02 derivatives | 14-3-3σ/c-abl | CML | [80] |
| Difopein | 14-3-3/Raf-1 | cancer | [77] |
| FOBISIN101 | 14-3-3/PRAS40 14-3-3/Raf-1 |
cancer | [115] |
| Fragment C3 and related compounds | 14-3-3ζ/SOS | cancer | [105] |
| Inosine phosphate | 14-3-3σ/c-abl | CML | [84] |
| Macrocyclic peptides | 14-3-3ζ/ExoS | Pseudomonal infection | [78] |
| pS214Tau peptides | 14-3-3ζ/tau | Alzheimer’s disease | [87] |
| Pyridoxal phosphate | 14-3-3σ/c-abl | CML | [84] |
| R18 | 14-3-3ζ/Raf-1 | --- | [76] |
| UTK01 | 14-3-3ε/ezrin-radixinmoesin | notochord development | [85] |
| PPI stabilizers | |||
| Cotylenin A | 14-3-3/PMA | leukemias | [90, 91] |
| Disulfide fragments | 14-3-3σ/ERα | breast cancer | [75] |
| Epibastatin | 14-3-3/PMA | --- | [108] |
| FC-A | 14-3-3/PMA | cancer spinal cord injury |
[88] [102] |
| FC derivatives | cancer spinal cord injury |
[93] [103] |
|
| DP-005 | 14-3-3/p65 | cancer, stroke | [112] |
| FC-NCPC | --- | spinal cord injury | [103] |
| FC-THF | 14-3-3ơ/TASK3 | cancer | [99] |
| ISIR-005 | 14-3-3ζ/Gab2 | CML | [98] |
| ISIR-042 | --- | cancer | [100] |
| ISIR-050 | --- | cancer | [101] |
| NV-1, NV-2, NV-3 | 14-3-3/TAZ | cancer | [110] |
| 6 new derivatives | 14-3-3σ/TASK | cancer | [104] |
| Pyrollidone 1 and derivatives | 14-3-3/PMA | --- | [107, 108] |